Michael Young, MD
Geriatric Medicine · Prescott, ARNPI 1124026836
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.
Across 40 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$139
- Xeris Pharmaceuticals, Inc.$92
- Novo Nordisk$64
- Pfizer$62
- Merck$61
- AbbVie$60
- plus $202 from 6 others
What the payments were for
- Food & beverage$681100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 9 | $139 |
| Xeris Pharmaceuticals, Inc. | 6 | $92 |
| Novo Nordisk | 4 | $64 |
| Pfizer | 3 | $62 |
| Merck | 4 | $61 |
| AbbVie | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| GSK | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| AstraZeneca | 1 | $20 |
| Smith+Nephew | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
How this compares
$681 in reported general payments places this provider in the 75th percentile of 40 geriatric medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 498 | $167,585 |
| MounjaroTirzepatide | 80 | $114,210 |
| JanuviaSitagliptin Phosphate | 186 | $74,806 |
| JardianceEmpagliflozin | 103 | $58,079 |
| RexultiBrexpiprazole | 57 | $51,265 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $45,178 |
| FarxigaDapagliflozin Propanediol | 66 | $41,681 |
| LinzessLinaclotide | 50 | $41,300 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 54 | $39,722 |
| Potassium Chloride | 412 | $32,217 |
| OzempicSemaglutide | 29 | $28,112 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 110 | $23,085 |
| VraylarCariprazine Hcl | 15 | $21,775 |
| XareltoRivaroxaban | 50 | $21,725 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $20,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $167,585498 claims |
| Lilly USA, LLCMounjaro | $18 | $114,21080 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $20 | $92,455153 claims |
| MerckJanuvia, Belsomra | $61 | $86,097211 claims |
| AbbVieLinzess, Vraylar, Restasis | $60 | $73,28380 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $50 | $51,26557 claims |
| GSKTrelegy Ellipta | $50 | $45,17842 claims |
| Novo NordiskOzempic, Rybelsus | $64 | $42,88642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 40 geriatric medicine providers in Arkansas.
Other geriatric medicine in Prescott
- Larry JohnsonNorth Little Rock$13K
- Oumitana KajkenovaLittle Rock$5K
- Evgueni RoudachevskiLittle Rock$3K
- Gohar AzharLittle Rock$2K
- Koyia FiguresWest Memphis$2K
- Maria Christina JuditSpringdale$1K
- Victoria AkinsLittle Rock$1K
- Raluca Rosca SichitiuJonesboro$747
- Thirumal DubbakaLittle Rock$683
- Maneetha KodaliLittle Rock$668
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.